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Research Paper
Neuropeptide Y inhibits the trigeminovascular
pathway through NPY Y1 receptor: implications
for migraine
Margarida-Martins Oliveiraa,b,c, Simon Akermanb, Isaura Tavaresc, Peter J. Goadsbya,b,*
Abstract
Migraine is a painful neurologic disorder with premonitory symptomatology that can include disturbed appetite. Migraine
pathophysiology involves abnormal activation of trigeminocervical complex (TCC) neurons. Neuropeptide Y (NPY) is synthesized in
the brain and is involved in pain modulation. NPY receptors are present in trigeminal ganglia and trigeminal nucleus caudalis
suggesting a role inmigraine pathophysiology. The present study aimed to determine the effect of systemic administration of NPY on
TCC neuronal activity in response to dural nociceptive trigeminovascular activation. We performed in vivo electrophysiology in
anesthetized rats, administered NPY (10, 30, and 100 mg·kg21), and investigated the receptors involved by studying NPY Y1 (30
mg·kg21), Y2 (30mg·kg
21), and Y5 receptor agonists (100·mg·kg
21), and NPYY1 receptor antagonist (30mg·kg
21). NPY (30 and 100
mg·kg21) significantly reduced TCC neuronal firing in response to dural-evoked trigeminovascular activation, but only NPY (30
mg·kg21) significantly reduced spontaneous trigeminal firing. NPY Y1 receptor agonist also significantly reduced dural-evoked and
spontaneous TCC neuronal firing. NPY (10mg·kg21), NPY Y2, and Y5 receptor agonists, and the NPY Y1 receptor antagonist had no
significant effects on nociceptive dural-evoked neuronal firing in the TCC or spontaneous trigeminal firing. This study demonstrates
that NPY dose dependently inhibits dural-evoked trigeminal activity, through NPY Y1 receptor activation, indicating antinociceptive
actions of NPY in a migraine animal model. Based on the role of NPY in appetite regulation, it is possible that disruption of the NPY
system might explain changes of appetite in migraineurs.
Keywords: Neuropeptide Y, Migraine, Trigeminovascular, Headache, Appetite
1. Introduction
Migraine is considered a complex brain disorder3,22 and is the sixth
most common cause of disability in the world.19 Neuroimaging
studies in the premonitory phase, which represents the earliest
clinical manifestations of the migraine attack,23 have demonstrated
hypothalamic activation,32 while a somewhat different hypotha-
lamic site is activated during the attack.13 This is in agreement with
earlier animal studies,6,7,11,31 establishing the hypothalamus as an
important brain area in migraine pathophysiology. Disturbed
appetite, such as thirst, hunger, or food craving, or feeding
schedules have been reported anecdotally as triggers,9 or as
symptoms in the premonitory phase of the migraine attack.14,18,43
Importantly, these premonitory symptoms are regulated in part by
the hypothalamus that in turn implicates appetite-related neuro-
peptides, including neuropeptide Y (NPY).
NPY is a peptide hormone known to be involved in pain
modulation,24 appetite control, and circadian rhythm synchroniza-
tion30,39 and is present in central and peripheral nervous systems,
but is most abundantly expressed in the brain. In the human brain,
NPY expression is highly concentrated in hypothalamic nuclei,
basal ganglia, and limbic system.1 NPY potentially acts on six G
protein–coupled receptor subtypes (Y1-6), with theNPYY3 receptor
not yet cloned. The NPY y6 receptor only exists as a functional
receptor in the mouse and rabbit.53 The NPY Y4 receptor mRNA is
the least abundant and has the most restricted distribution pattern
of all NPY receptor subtypes in the central nervous system.40 In
addition, the available agonist for the human NPY Y4 receptor has
a short mean half-life of only approximately 6 minutes, limiting its
bioactivity in vivo.2 NPY has been shown to be involved in
antinociception in different pain models,28,29,38 although not
studied yet in migraine. NPY causes vasoconstriction of human
middle meningeal and cerebral arteries16,25 and inhibits plasma
protein extravasation through NPY Y2 receptors.
52
These data suggest that NPY could play an important role in
the pathophysiology of primary headache disorders. In the
present study, we used an animal model of acute dural
nociceptive activation of the trigeminovascular system, which
has been shown to represent a valid model to study migraine
neurobiology and has reliably predicted clinical efficacy of many
therapeutics, such as triptans.5,8 We determined the effects of
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intravenous administration of NPY in trigeminovascular nocicep-
tive responses, relevant to headache, and dissected the relative
contributions of specific NPY receptors.We explored NPYY1, Y2,
and Y5 receptor pharmacology in this animal model because
mRNA encoding human NPY Y1 and NPY Y2 receptors is
detected in the cerebral and meningeal arteries and in human
trigeminal ganglia47; NPY Y1, Y2, and Y5 receptors are present in
rodent trigeminal nucleus,40 and these receptors have a major
role in hypothalamic appetite control.53 Some data have been
presented previously in preliminary form.34–36
2. Materials and methods
All experiments were conducted under a license of the University
of California, San Francisco Institutional Animal Care and
UseCommittee (IACUC) and conforming to the National Institutes
of Health Guide for the Care and Use of Laboratory Animals,
and adhered to the guidelines of the Committee for Research
and Ethical Issues of International Association for the Study
of Pain.56
2.1. Surgical preparation
Male Sprague-Dawley rats (275-365 g; n 5 57, Charles River,
MA) were housed (2-3 animals per cage) in temperature and light
controlled rooms for at least 7 days before use with access to
food and water ad libitum. On the day of the study at
approximately 8 to 9 AM, they were anesthetized with sodium
pentobarbitone (60 mg·kg21, intraperitoneally; Nembutal, Lund-
beck, Deerfield, IL) for induction, and anesthesia was maintained
with a propofol solution (PropoFlo, 25-30 mg·kg21·h21,
intravenous infusion; Abbott Animal Health, Abbott Park, IL).
During electrophysiological recording, the animals were para-
lyzed with pancuronium bromide (Pavulon, Hospira, Inc., Lake
Forest, IL), 0.4 mg initially, and maintained with 0.2 mg every 30
minutes. The animals were monitored during the surgical
procedure for changes in body temperature, respiratory rate,
and blood pressure as described previously.4 After fixation of the
skull in a stereotaxic frame (Kopf Instruments, Tujunga, CA), rats
were ventilated (Ugo Basile, Comerio, Italy) with oxygen-enriched
air, 2 to 2.5 ml, 80 to 100 strokes per minute, and end-tidal CO2
was monitored (CapStar-100; CWE Inc, Ardmore, PA) and kept
between 3.5% and 4.5%. Arterial blood pressure and end-tidal
CO2 were displayed and recorded on a personal computer using
an online data analysis system (Power 1401) and Spike2 v5.21
software (Cambridge Electronic Design, Cambridge, United
Kingdom). At the end of each experiment, animals were killed
with a lethal dose of intravenously administered pentobarbital and
phenytoin sodium (Euthasol; Virbac AH, Inc, Fort Worth, TX).
2.2. Middle meningeal artery and trigeminocervical
complex exposure
To gain access to the dura mater and middle meningeal artery
(MMA), the skull was exposed and a craniotomy of the parietal
bone was performed with saline-cooled drilling and the area was
covered in mineral oil. For access to the trigeminocervical
complex (TCC), the muscles of the dorsal neck were separated,
a cervical (C1) laminectomy was performed and the dura mater
was incised to expose the brainstem at the level of the caudal
medulla oblongata. A piezoelectric motor–driven microelectrode
positioner attached to a micromanipulator was used to locate the
optimal recording site, allowing movements of the recording
electrode in 5-mm steps. After completing the surgery, the
animals were left to stabilize for at least 1 hour before
electrophysiological recordings.
2.3. Stimulation of the MMA and recording from the TCC
After removal of the parietal bone within the cranial window,
a bipolar stimulating electrode (NE200; Rhodes Medical Instru-
ments, Summerland, CA) connected to a stimulus isolation unit
(SIU5A; Grass Instruments, Quincy, MA) was placed on the intact
dura mater adjacent to the MMA for electrical stimulation of the
perivascular afferents of the trigeminal nerve (Fig. 1A). Stimulation
of primary trigeminal afferents was performed with supramaximal
square-wave pulses generated by a Grass S88 stimulator (Grass-
Instruments, USA). Dural nociceptive neurons in the TCC were
identified by applying square-wave electrical stimuli (8-15 V, 0.15-
0.25milliseconds, 0.4-0.5Hz, 20 sweeps) to theduramater. These
stimulation parameters were able to activate trigeminal Ad fibers,
with approximate latencies between 3 and 20 milliseconds, and
less frequently C fibers, with latencies.20 milliseconds and up to
80 milliseconds, which innervate the dura mater.
Extracellular recordings were made from neurons in the TCC,
activated by dural stimulation, with cutaneous facial receptive fields
(Fig. 1B), using tungsten microelectrodes (World Precision Instru-
ments, Sarasota, FL; impedance 0.5-1.0 MV, measured at 1 kHz
in 0.9% saline, with tip diameter of 0.5 mm). The signal from the
recording electrode attached to a high-impedance headstage
preamplifier (NL100AK; Neurolog, Digitimer, Welwyn Garden City,
Hertfordshire, UnitedKingdom)was fed through anACpreamplifier
(Gain x2000; Neurolog NL104). The signal was then band-pass
filtered (Neurolog NL126) from 300 Hz to 20 kHz and passed
through a Hum Bug 60 Hz noise eliminator (Quest Scientific,
Vancouver, BC, Canada) for removal of line interference before
further amplification using an AC-DC second-stage amplifier
(Neurolog NL106) with a gain range of 320 to 390 (total gain
used approximately 25,000-40,000 Hz). The obtained electrical
signal was then fed through a gated amplitude discriminator
(Neurolog NL201) and an analog-to-digital converter (Power 1401;
Cambridge ElectronicDesign,Cambridge,UnitedKingdom) and to
a microprocessor-based personal computer (Dell Latitude) using
Spike 2 v5.21 software (Cambridge Electronic Design) where the
signal was processed and stored. Additionally, it was fed to
a loudspeaker through a power amplifier for audio monitoring
(Neurolog NL120) and displayed on analog and digital storage
oscilloscopes (Goldstar, LG Precision, Seoul, Korea; and Metrix
Electronics, Hampshire, UK, respectively) to assist isolation of
action potentials from adjacent cell activity and noise.
2.4. Characterization of neurons
Neurons were characterized for their cutaneous and deep receptive
fields. The cutaneous receptive field was assessed in all 3 territories
of the trigeminal innervation and identified as the recording electrode
was advanced in the spinal cord. The receptive field was assessed
for both nonnoxious inputs, with gentle brushing using a cotton tip
applicator, and noxious inputs, with pinching with forceps that was
painful when applied to humans. When a neuron sensitive to the
stimulation of the ophthalmic (V1) dermatome of the trigeminal nerve
was identified, itwas tested for convergent input from theduramater.
2.5. Experimental design
Trains of 20 stimuli were delivered at 5-minute intervals to assess
the baseline response to dural electrical stimulation. Responses
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were analyzed using poststimulus histograms with a sweep
length of 100 milliseconds and a bin width of 1 milliseconds that
separated Ad-fiber-activated (3-20 milliseconds) and C-fiber-
activated (20-80milliseconds) firing. Spontaneous activity (spikes
per second, Hz) was recorded for 150 s preceding the dural
stimulation using peristimulus histograms. Background activity
was analyzed as cumulative rate histograms in which neuronal
activity gated through the amplitude discriminator was collected
into successive bins.
When stable baseline values of the stimulus-evoked responses
were achieved (mean of 3 stimulation series that would not differ
more than 10%) and cutaneous and deep receptive field inputs
from the ophthalmic division of the trigeminal nerve were
obtained, responses were tested for up to 60 minutes after
pharmacological or vehicle intervention.
2.6. Drugs
TCC neuronal responses to electrical dural afferent stimulation
were tested with NPY human (Sigma-Aldrich) in a dosage of 10
mg·kg21 (n 5 6), 30 mg·kg21 (n 5 9), and 100 mg·kg21 (n 5 8).
The dose of NPY at 10mg·kg21 (intravenously) was chosen based
on studies of experimental vasodilation in the dura mater49 and
escalated thereafter for a dose–response effect.
To investigate NPY receptor pharmacology, 3 different NPY
receptor agonists (Tocris Bioscience, Minneapolis, MN) were
administered intravenously: NPY Y1 receptor agonist ([Leu31,
Pro34]-NPY [human], 30 mg·kg21, n 5 10); NPY Y2 receptor
agonist (PYY 3-36, 30 mg·kg21, n 5 6); and NPY Y5 receptor
agonist ([cPP1-7,NPY19-23,Ala31,Aib32,Gln34]—hPancreatic
Polypeptide, 100 mg·kg21, n 5 6). The doses of the agonists
were selected on the basis of earlier studies in which NPY
exhibited subnanomolar affinities to the Y1, Y2, and Y5 receptors
and nanomolar binding affinity to the Y4 receptor.
12 In addition,
each of the Y1, Y2, and the Y5 receptor agonists used in this study
show similar binding affinities to their receptors, 0.39 nM,37
0.3 nM,15 and 0.24 nM,12 respectively. Thus, based on the
binding of NPY to each receptor, and the similarity of responses to
each agonist, similar doses were chosen. Finally, to determine
whether there was any endogenous tonic effects of the NPY Y1
Figure 1.Overview of the experimental setup and neuronal characteristics. (A) Experimental setup with dural electrical stimulation and recording of neurons in the
trigeminocervical complex (TCC). (B) All neurons studied were wide dynamic range, responsive to both noxious and innocuous stimulation, with cutaneous
receptive field in the first (V1; ophthalmic) division of the trigeminal nerve. (C) The location of recording sites in the TCC from which recordings of nociceptive
neurons, receiving convergent input from the duramater and facial receptive field, weremade. The locations were reconstructed from lesions (•) and are located in
laminae III-V, predominantly in lamina V. (D) A histological example for the lesionmark (as indicated by the arrow) of the recording site in the TCC (lamina V), marked
by electrothermolytic lesion (4-6 mA for 60 sec). The section was counterstained with cresyl violet. (E) An original tracing from a typical unit (second-order neurons)
responding to electrical stimulation of the dura mater adjacent to the middle meningeal artery (latencies in the Ad-fiber range). Black arrow represents stimulus
artifact.
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receptor in the modulation of trigeminal nociceptive transmission,
a highly selectiveNPYY1 receptor antagonist (BVD10) in a dosage
of 30 mg·kg21 (n 5 5) was administered alone using the same
scheme described above. The optimal dose of the antagonist was
derived from preliminary experiments showing 30 mg·kg21 pro-
duced a maximum blood pressure increase of 11 6 1%. Sterile
water alone was used as the vehicle control group (n 5 7) and
naratriptan in a dosage of 10 mg·kg21 (n5 6) as a positive control
to these responses. All drugs were dissolved in sterile water.
2.7. Postsurgical examination of tissue
At the end of the experiment and after terminal anesthesia, an
electrothermolytic lesion was made in the TCC by passing
a current down the recording electrode (4-6 mA for 60 s) to
confirm the location of the recording electrode. The brain and
cervical spinal cord were removed. Serial 60-mm-thick coronal
sections were cut from themedulla oblongata and C1-C3 spinal
segments, stained for cresyl violet, and visualized under the light
microscope (Axioplan Microscope; Carl Zeiss GmbH, Jena,
Germany), using the rat brain atlas Paxinos andWatson, 200541
for reference.
2.8. Statistical analysis
Data collected for Ad fibers represent the normalized data for
the number of cells firing over a 10-milliseconds time period in
the region 4 to 20 milliseconds poststimulation over the 20
collections and expressed as mean 6 SEM. Spontaneous
activity was measured in cell firings per second (Hz). Statistical
analysis was performed using IBM SPSS 20.0 software.
To measure whether there was a significant effect across the
60-minutes time course within a drug group of animals, we
used analysis of variance for repeated measures with
Bonferroni post hoc correction for multiple comparisons. If
Mauchly test of sphericity was violated, appropriate correc-
tions to degrees of freedom were made according to
Greenhouse–Geisser.17 Student paired t test was used for
post hoc analysis of the significance of individual time
points, using the average of the 3 baselines for comparison.
Statistical significance was assumed at P , 0.05.
3. Results
3.1. Electrophysiological data
Recordings were made from a total of 63 neurons in 57 rats.
Animals studied had a mean body weight of 319 6 3.2 g.
Extracellular recordings in the TCC were made from wide-
dynamic-range neurons, responsive to dural (MMA) stimulation
(Fig. 1A), and with cutaneous receptive fields in the ophthalmic
division (V1) of the trigeminal nerve (Fig. 1B). Most neuronswere
located in lamina V of the dorsal horn at the level of the
cervicomedullary junction (with a few neurons in laminae III-IV),
at an average depth of 476 6 27 mm, and the electrode
placement was confirmed in all animals by an electrothermolytic
lesion in the TCC (Fig. 1C, D). Neurons responding to dural
electrical stimulation responded with an average latency of 10.8
6 0.2 milliseconds (range 4-20 milliseconds, an example of
evoked neuronal firing can be seen in Fig. 1E) and hence were
classified as Ad fibers. The mean ongoing spontaneous firing
rate was 23.8 6 2.0 Hz with most neurons responding
between 10 and 20 Hz; this is within the same range as that
demonstrated in previous studies.4
3.2. Controls
Intravenous injection of sterile water (vehicle control) had no
significant effect on Ad-fiber responses (F3.1,18.85 0.9; P5 0.42)
and ongoing spontaneous activity (F1.8,10.9 5 0.3; P 5 0.72) of
trigeminal second-order neurons during the 60-minutes time
period.
Naratriptan 10 mg·kg21 (Sigma-Aldrich) was also tested in
another group of animals as a positive control for inhibition of
second-order neurons.21 Extracellular recordings showed a signif-
icant decrease of dural-evoked nociceptive responses (F2.2,10.9 5
3.9; P 5 0.048) throughout the 60 minutes, reaching a maximum
inhibition of 27% at 30 minutes (t5 5 3.592; P 5 0.016) and
60 minutes (t5 5 4.663; P 5 0.006). Ongoing spontaneous
background activity was also significantly reduced (F2.1,10.55 12.4;
P 5 0.002) within the TCC after naratriptan administration
across the 60-minutes cohort. A maximum inhibition of 58% was
achieved at 60 minutes when compared with the baseline (t5 5
4.472; P 5 0.007).
3.3. NPY dose dependently inhibits neurotransmission in the
trigeminovascular system
NPY (10 mg·kg21) did not have any significant effect on dural-
evoked nociceptive firing in the TCC (F2.2,11.15 0.3; P5 0.78) or
the ongoing spontaneous activity (F1.6,8.2 5 1.3; P 5 0.30). NPY
(30 mg·kg21) significantly inhibited dural-evoked responses (F8,64
5 3.8; P5 0.001), with a maximal inhibition of 17% at 60 minutes
(t8 5 3.284; P 5 0.011). Ongoing spontaneous activity was also
significantly inhibited (F8,645 2.7;P5 0.012) over the 60-minutes
cohort, with a maximum inhibition of 23% at 60 minutes when
compared with baseline (t8 5 2.507; P 5 0.037). Likewise, NPY
(100 mg·kg21) significantly reduced nociceptive neuronal firing
within the TCC (F3.1,21.5 5 8.5; P 5 0.001). Maximal inhibition of
20% was achieved at 30 minutes when compared with baseline
(t7 5 5.645; P 5 0.001). At this dose, there was no significant
effect on spontaneous neuronal firing (F3.6,25.2 5 0.6; P 5 0.67).
The dural-evoked neuronal responses of human NPY (30 mg·kg-1
and 100 mg·kg21) did not return to baseline 60 minutes or
90 minutes after the administration (data not shown).
3.4. NPY Y1 receptor agonist significantly reduces the
activation of the trigeminovascular system
To dissect the specific NPY receptor that mediates this inhibitory
response in the trigeminovascular system, we also administered
selective agonists. The NPY Y1 receptor agonist (30 mg·kg
21)
significantly reduced the dural-evoked neuronal firing (F8,725 3.9;
P 5 0.001), reaching a maximum inhibition of approximately 22%
at 15 minutes (t95 4.419; P5 0.002). It also significantly reduced
the ongoing spontaneous responses (F8,725 2.4; P5 0.022), with
the greatest point of inhibition at 45 minutes, by 29% below
baseline firing (t95 2.545;P5 0.031). Administration of theNPYY2
receptor agonist (30 mg·kg21) had no significant effect on
nociceptive dural-evoked firing (F1.6,8.15 0.3;P5 0.70) or ongoing
spontaneous neuronal firing (F1.9,9.9 5 1.0; P 5 0.386).
In a pilot study using the NPYY5 receptor agonist (30mg·kg
21),
there was no significant difference in neuronal firing compared
with baseline values (data not shown); thus, we decided to
perform the next experiments using a dose of 100 mg·kg21. NPY
Y5 receptor agonist (100 mg·kg
21) had no significant effect on
dural-evoked nociceptive responses (F3.1,15.7 5 0.8; P 5 0.51)
and ongoing spontaneous neuronal activity (F1.4,6.8 5 1.0;
P 5 0.375) in the TCC.
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Taken together, these data demonstrate that NPY is able to
inhibit the effects of dural-evoked trigeminovascular activation in
a dose-dependent manner (Fig. 2A, B) and these effects seem to
be specific to the NPY Y1 receptor (Fig. 2C, D).
3.5. NPY Y1 receptor antagonist has no significant effect on
the activation of the trigeminovascular system
Intravenous administration of a highly selective NPY Y1
receptor antagonist (30 mg·kg21) had no significant effect
on Ad-fiber responses to dural stimulation (F3.0,12.0 5 0.8;
P 5 0.51) or ongoing spontaneous neuronal firing
(F1.4,5.6 5 0.8; P 5 0.45).
3.6. Blood pressure effect
In all experiments, blood pressure was at physiological levels
(92.66 2.4 mm Hg) before injections. Intravenous administration
of NPY human 10, 30, and 100 mg·kg21 significantly increased
mean arterial blood pressure immediately after injection. NPY
human 10, 30, and 100 mg·kg21 reached a maximum increase of
16 6 5% (t5 5 3.954; P 5 0.011), 17 6 2% (t8 5 6.334; P 5
0.000), and 496 5% (t75 7.241; P5 0.000), respectively. Blood
pressure values slowly recovered to preinjection values after
approximately 12 6 3 minutes (t5 5 3.296; P 5 0.022), 10 6 2
minutes (t85 5.525; P5 0.001), and 196 3minutes (t75 6.500;
P 5 0.000) postinjection, respectively. Original data showing
Figure 2. Effects of neuropeptide Y (NPY) and selective NPY Y receptor modulation on dural-evoked neuronal firing in the trigeminocervical complex (TCC).
(A) Time course changes in the average response of dural-evoked Ad-fiber trigeminal neuronal firing in response to human NPY (100 mg·kg21), which significantly
decreased neuronal responses across the 60-min study. Vehicle has no effect on responses. (B) Bar graph of themaximum effect at the “30-minutes time point” of
the change from baseline of dural-evoked Ad-fiber activity in the TCC. NPY (10-100 mg·kg21) dose dependently inhibited dural-evoked neuronal responses, with
both 30 and 100 mg·kg21 significantly inhibiting dural-evoked Ad-fiber activity in the TCC. Water for injection (control) had no effect and naratriptan (10 mg·kg21)
also significantly inhibited responses. (C) Time course changes in the average response of dural-evoked Ad-fiber trigeminal neuronal firing in response to
a selective NPY Y1 agonist (30 mg·kg
21), which significantly decreased trigeminal responses across the 60-minutes study. Vehicle has no effect on responses.
(D) Bar graph of the maximum effect at the “15-minutes time point” of the change from baseline of dural-evoked Ad-fiber activity in the TCC after selective NPY
receptor agonists and Y1 antagonist. Only the NPY Y1 receptor agonist (30 mg·kg
21) significantly inhibited dural-evoked Ad-fiber activity in the TCC. The selective
NPY Y2 and Y5, and Y1 antagonist had no effect on responses. Data are presented as mean6 SEM; *P, 0.05, **P, 0.005 significance when compared with an
average of the 3 baselines using Student paired t test.
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blood pressure and spontaneous TCC neuronal firing before
intravenous injection of NPY 30 mg·kg21 and for the following
60 minutes can be seen in Fig. 3. Blood pressure slowly returned
to baseline levels within 15 minutes independent of the maximal
dural-evoked and spontaneous TCC neuronal inhibition, which
occurred at 60 minutes postinjection.
NPY Y1 receptor agonist (30 mg·kg
21) significantly increased
the mean arterial blood pressure, maximally by 67 6 5% (t9 5
17.720; P 5 0.000), slowly returning to baseline after 16 6 5
minutes (t9 5 3.149; P 5 0.012). However, the NPY Y2 and the
NPY Y5 receptor agonist had no significant effects on blood
pressure. The NPY Y1 receptor antagonist (30 mg·kg
21) reached
a maximum increase of 11 6 1% (t4 5 8.948; P 5 0.001) after
injection, returning to preinjection values after 14 6 2 minutes
(t4 5 4.740; P 5 0.009). Naratriptan decreased the blood
pressure by 8 6 5% (t5 5 1.49; P 5 0.195) after injection and
never returned to preinjected blood pressure values.
4. Discussion
The data demonstrate that NPY can modulate nociceptive
trigeminovascular transmission in second-order neurons of the
TTC after peripheral systemic administration. This effect could be
mimicked by an NPY Y1 receptor agonist but not by NPY Y2, and
Y5 receptor agonists. Moreover, there was no resting effect of the
NPY Y1 receptor on ongoing spontaneous trigeminal firing as
evidenced by no effect of an NPY Y1 receptor antagonist, and
consistent with themodest response and lack of a dose–effect for
NPY itself. These data are consistent with the existence of an
inhibitory NPY Y1 receptor in the TTC. These results are in
agreement with the antinociceptive role of NPY in other animal
models of different pain states.
Our findings reveal a potential involvement of NPY in migraine
pathophysiology, through its ability to modulate the firing of dural-
evoked nociceptive second-order trigeminovascular neurons.
These data contrast with previous studies that also used dural
nociceptive stimulation. In these previous experiments, neuro-
peptide levels were measured in the extracranial vasculature,
taken from external jugular vein blood, after superior sagittal sinus
stimulation and were unchanged,55 in contrast to calcitonin
gene-related peptide55 and pituitary adenylate cyclase–activating
peptide.54 However, this may reflect the locus of release and
action in the central nervous system in contrast to the more
widespread release of other neuropeptides involved in migraine.
For example, localized release of NPYwithin hypothalamic nuclei,
where we know it is released during feeding and impact migraine
symptoms, would not be detected in such assays. It is also
important to reflect that NPY readily gets into the brain, and our
data demonstrate that it is able to attenuate the responses
of second-order trigeminovascular neurons to dural-evoked
stimulation.
A further aim was to investigate whether NPY exerts tonic
antinociceptive control of TCC neurons, by administering an NPY
Y1 receptor antagonist in our model. Spinal NPY is known to exert
a tonic, long-lasting inhibitory control of spinal nociceptive
transmission, as demonstrated by NPY knockdown or intrathecal
administration studies.45 We did not see an effect on neuronal
firing after NPY Y1 antagonist administration, which suggests that
NPY does not exert a tonic control of TCC neuronal firing.
Concerning the cardiovascular effects in our study, the
inhibitory response of NPY is not due to blood pressure changes
since the time course of blood pressure elevation is different from
the inhibition of the trigeminal neurons within the TCC. This is
confirmed when the blood pressure returns to baseline values at
some point of the study and the TCC neuronal firing is significantly
inhibited across the 60-min study.
In our study, we chose to administer NPY systemically. This
allowed us to directly translate findings into the clinical setting for
Figure 3. Blood pressure (BP) effects of neuropeptide Y (NPY). Original recording of BP and spontaneous trigeminocervical complex (TCC) neuronal firing before
intravenous injection of NPY 30 mg·kg21 and for the following 60 minutes. The BP increased (8%) following injection and slowly returned to baseline levels within
15minutes; it was reduced by 8% at 60minutes compared with baseline. In contrast, maximal spontaneous TCC neuronal inhibition occurred at 60minutes, here
to 40% of the baseline.
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potential therapeutics, and because we know NPY is able to
cross the blood–brain barrier,27 it suggests it is likely to acting
centrally. Based on this probable action in the brain, we believe
the most likely targets in modulating trigeminovascular nocicep-
tive transmission in this study are at the level of the hypothalamus
and also directly on the TCC neurons. We have tried to rationalize
these potential sites of action with what we know of NPY and how
it might fit into a role in migraine pathophysiology. Reported
migraine triggers (skipping meals) or symptoms (appetite
changes) might act through NPY because altered feeding
behavior is able to interfere with NPY pathways. For example,
NPY mRNA expression is upregulated by fasting in the
hypothalamic arcuate nucleus (ARC)48; NPY Y1 receptor mRNA
is elevated in the hypothalamus in response to fasting and food
restriction50; and following food deprivation, NPY is released from
ARC-projecting neurons into the hypothalamic paraventricular
nucleus (PVN) in vivo.26 The PVN is a pivotal nucleuswith second-
order neurons that integrates signals from ARC first-order
neurons (such as NPY-containing neurons), and then sends
downstream information to the nucleus tractus solitarii (NTS) to
control appetite.10 Specific hypothalamic nuclei are thought to
have a major role in migraine pathophysiology.33 It has been
shown that PVN modulates basal and nociceptive meningeal-
evoked activity of trigeminal neurons, containing neurons known
to project directly to the trigeminal nucleus caudalis.42,46 Taking
into consideration that NPY activity within the ARC-PVN neural
circuit is seen as a homeostatic response to perturbations of
energy balance, our results showing an inhibition of dural-evoked
nociception and spontaneous TCC neuronal firing might indicate
that NPY could be acting within the PVN to modulate the TCC
through direct projections.
In addition to this, ARC neurons project to many pain
modulatory nuclei in the brainstem, including the periaqueductal
gray, nucleus tractus solitarii, dorsal raphe nucleus, and locus
coeruleus,44 with NPY-immunoreactive neuronal projections
from the ARC to dorsal raphe nucleus and locus coeruleus in
the rat.51 Moreover, intra-ARC administration of NPY exerts an
antinociceptive effect in intact rats and in rats with inflammation
through NPY Y1 receptor activation.
29 Because ARC contains
a high concentration of NPY-producing neurons and NPY
receptors, systemic NPY in our study could also act directly in
the ARC with further actions either in the PVN or other pain
modulation nuclei to induce inhibition of nociceptive activation of
trigeminovascular neurons.
In conclusion, hypothalamic nuclei are in key positions to
mediate the triggering of migraine and trigeminovascular activa-
tion, modulating migrainous symptoms through appetite
changes. In this study, we show that NPY, through its NPY Y1
receptor, may be involved in such a pathway. The data offer
further pharmacologic therapeutic targets to those currently
under development,20 although there is a chance of increased
appetite with the NPY Y1 receptor agonist approach, which could
be offset by chronic systemic administration of low doses of an
NPY Y1 agonist. Investigating the pathophysiological mecha-
nisms taking place during the earlier phase of the migraine attack
is clearly important to understand migraine and its associated
symptoms.
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